The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E

• DOI: 10.1038/s41541-025-01078-0
• Publication Date: 2025-02-06T14:00:57Z
• Authors: M. Sanni Ali; Lisa Stockdale; Issaka Sagara; Issaka Zongo; Rakiswendé Serge ...; Almahamoudou Mahamar; Frédéric Nikièma; Amadou Tapily; Frédéric Sompougdou; Modibo Diarra; Duncan Bellamy; Samuel Provstgaar...; Charles Zoungrana; Djibrilla Issiaka; Alassane Haro; Koualy Sanogo; Abdoul Aziz Sienou; Mahamadou Kaya; Seydou Traore; Oumar M. Dicko; Youssouf Kone; Hama Yalcouye; Ismaila Thera; Kalifa Diarra; Paul Snell; Opokua Ofori-Anyinam; Chris Ockenhouse; Cynthia Lee; Katie Ewer; Halidou Tinto; Abdoulaye Djimde; Jean-Bosco Ouedraogo; Alassane Dicko; Daniel Chandramohan; Brian Greenwood
• Keywords: Circumsporozoite protein; Booster dose; Booster (rocketry)

Abstract The recently deployed RTS,S/AS01 E malaria vaccine induces a strong antibody response to the circumsporozoite protein (CSP) on surface of Plasmodium falciparum sporozoite which is associated with protection. anti-CSP titre falls rapidly after primary vaccination, decline in efficacy, but and protective can be partially restored by booster dose vaccine, this also transitory. In many malaria- endemic areas Africa, children are at risk malaria, including severe until they five years age or older sustain protection from for period vaccination , repeated doses may required. However, there little information about immune . malaria-endemic burden largely restricted rainy season and, therefore, recent trial conducted Burkina Faso Mali explored impact annual given immediately prior transmission reached years. Anti-CSP titres were measured sera obtained randomly selected subset enrolled collected before one month three priming four using GSK ELISA developed University Ghent these samples, multiplex assay Oxford. Three induced (GMT 368.9 IU/mL). Subsequent annual, seasonal strong, lower, response; GMT fourth was 128.5 IU/mL. Children whose upper middle terciles post had lower incidence during following year than lowest tercile. Results Oxford Multiplex strongly correlated (Pearson’s correlation coefficient, r = 0.94; 95% CI, 0.93–0.95). Although declined high, although declining, level efficacy sustained suggesting that have been changes characteristics doses. Clinical Trials Registration NCT03143218.